'If You Want To Be A Millionaire, Stop Doing The 9-5': Grant Cardone Says Working 40 Hours A Week On An Average Salary Won't Make You Rich
In a blog post, Grant Cardone, the self-proclaimed “Benjamin Button of business,” shared his take on getting wealthy.
He’s bold and unapologetic when he says, “If you ever want to be a millionaire, you need to stop doing the nine to five and start doing 95.” Cardone is clear about his message: to create real wealth, you need to live in the fast lane, putting in 95 hours a week, not 40.
Don’t Miss:
Cardone doesn’t just question the traditional workweek – he believes it’s holding people back from their dreams. “Those who work only nine to five have given up on their dreams and are mostly spectators,” he says.
Now, more hours mean more work, more money – at least in theory. But what about the thousands of people who do work nine to 5, pay their bills and are left wondering if they’ll ever escape that paycheck-to-paycheck grind?
See Also: I’m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?
“There’s no shortage of money. Every dollar on this planet has been manufactured. There is a shortage of people doing 95 hours each week,” he explains. His advice comes from years of building businesses and investments that have landed him in the millionaire circle.
To him, there’s only one way to build wealth – grind. And it doesn’t stop, even for a guy like Cardone, who claims, “If you gave me $5 billion, I’d still be grinding tomorrow.”
A 9 to five job doesn’t necessarily mean financial stagnation but can present limits. A 2022 survey from the Federal Reserve revealed that the average American household’s net worth was just over $192,900. “You can’t save your way to being a millionaire making $60k,” Cardone says.
Trending: A billion-dollar investment strategy with minimums as low as $10 — you can become part of the next big real estate boom today.
Cardone bluntly adds, “You can, but you will be 90 years old. Who wants that?” He argues that working 95 hours a week pushes you into a realm of earning potential that traditional jobs can’t match. As he says, “You need to get your income up to $125K to get your head above water in today’s world.”
The Real Challenge: How to Earn More
He stresses the need for expansion: “Most experts are about contraction. I’m about expansion.” His critique of popular financial advice – like Suze Orman’s mantra to save and Dave Ramsey’s focus on avoiding debt – is a call to action for his followers to create income, not just manage it. “Learn to create the money,” he says, urging people to focus on making more, not just cutting costs.
Trending: Founder of Personal Capital and ex-CEO of PayPal re-engineers traditional banking with this new high-yield account — start saving better today.
His advice makes sense for entrepreneurs and business owners, but most full-time workers don’t have the same flexibility to scale their income at will. Many experts recommend a balanced approach: building side hustles, investing wisely and growing passive income streams alongside regular employment.
Can You Really Get Rich Working nine to 5?
The grind-it-out philosophy might work for those with entrepreneurial ambitions or those willing to work extra hours, but it’s not a universal solution. Studies suggest that financial independence is possible with strategic planning, smart investments and steady income growth – even on a 40-hour workweek.
The key is finding a balance that works for your goals and lifestyle. For some, that might mean extra hours, while for others, smarter financial moves do the trick. As Cardone says, “Be the Benjamin Button in your space and start making more Benjamins.”
Read Next:
Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.
Get the latest stock analysis from Benzinga?
This article ‘If You Want To Be A Millionaire, Stop Doing The 9-5’: Grant Cardone Says Working 40 Hours A Week On An Average Salary Won’t Make You Rich originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Chief Commercial Officer At Harmony Biosciences Sells $1.27M Of Stock
Jeffrey Dierks, Chief Commercial Officer at Harmony Biosciences HRMY, reported an insider sell on October 7, according to a new SEC filing.
What Happened: Dierks opted to sell 36,357 shares of Harmony Biosciences, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday. The transaction’s total worth stands at $1,274,546.
Monitoring the market, Harmony Biosciences‘s shares up by 0.35% at $34.5 during Tuesday’s morning.
Unveiling the Story Behind Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company’s product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Financial Milestones: Harmony Biosciences’s Journey
Revenue Growth: Harmony Biosciences’s revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 28.76%. This indicates a substantial increase in the company’s top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Insights into Profitability:
-
Gross Margin: Achieving a high gross margin of 81.4%, the company performs well in terms of cost management and profitability within its sector.
-
Earnings per Share (EPS): Harmony Biosciences’s EPS reflects a decline, falling below the industry average with a current EPS of 0.2.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.35.
Assessing Valuation Metrics:
-
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 17.63 is lower than the industry average, indicating potential undervaluation for the stock.
-
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.07, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company’s EV/EBITDA ratio 8.53 is below the industry average, indicating that it may be relatively undervalued compared to peers.
Market Capitalization Perspectives: The company’s market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Delving Into the Significance of Insider Transactions
Considering insider transactions is valuable, but it’s crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term “insider” pertains to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider’s new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
Exploring Key Transaction Codes
Delving into transactions, investors typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Harmony Biosciences’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AstraZeneca AZN announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia.
The latest agreement is likely to strengthen AstraZeneca’s cardiovascular pipeline, which is being studied for treating various cardiovascular diseases.
Year to date, shares of AstraZeneca have rallied 14.1% compared with the industry’s rise of 18.5%.
Image Source: Zacks Investment Research
More on AZN’s Latest Agreement
Per the deal, AZN will make an upfront payment of $100 million to CSPC. The company is also entitled to pay up to $1.92 billion for further development and commercialization milestones plus tiered royalties to CSPC.
Per the latest agreement with CSPC, AstraZeneca will gain access to the latter’s pre-clinical candidate, YS2302018, an oral Lp(a) disruptor, and develop the same for various cardiovascular diseases. The company will develop YS2302018 alone or in combination studies, including with the oral small molecule PCSK9 inhibitor, AZD0780.
Discovered by CSPC, YS2302018 has been shown to effectively prevent the formation of Lp(a), a form of low-density lipoprotein that plays a key role in transporting cholesterol in the bloodstream.
Per the company, the addition of YS2302018 to AZN’s cardiovascular pipeline might help patients to more effectively manage their dyslipidaemia and cardiometabolic diseases.
AZN’s Airsupra Meet Goal in BATURA Study
In a separate press release, AstraZeneca announced positive data from the phase IIIb BATURA study, which evaluated its pressurized metered-dose inhaler (pMDI), Airsupra (albuterol/budesonide).
Data from the study showed that treatment with Airsupra led to a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms versus as-needed albuterol in patients with intermittent or mild persistent asthma. This was the primary endpoint of the BATURA study.
Airsupra is approved for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and above in the United States. It is the first and only anti-inflammatory rescue medication for the given condition.
AZN’s Zacks Rank & Other Stocks to Consider
AstraZeneca currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. ANIP, ADMA Biologics, Inc. ADMA and Alnylam Pharmaceuticals, Inc. ALNY, each sporting a Zacks Rank #1 (Strong Buy) at present. In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have increased from 35 cents to 49 cents. Earnings per share estimates for 2025 have improved from 53 cents to 64 cents. Year to date, shares of ADMA have surged 346.5%.
ADMA’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 105.63%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Boeing Withdraws Contract Offer as Union Talks Break Down
(Bloomberg) — The crisis engulfing Boeing Co. took a dramatic turn after negotiations to resolve an almost monthlong strike collapsed and S&P Global Ratings warned it may cut the planemaker’s credit grade to junk.
Most Read from Bloomberg
Both the embattled company and the International Association of Machinists and Aerospace Workers blamed each other for the impasse. Boeing said the union made “non-negotiable demands,” while the IAM said the company was “hell-bent on standing on the non-negotiated offer.”
The impasse leaves Boeing with no clear path forward to overcome the debilitating strike, which has shut down production at its key commercial manufacturing base on the US west coast. Even before talks broke down, S&P highlighted the urgency to reach a resolution by pointing to an estimated $10 billion cash burn this year that will likely require additional funding to cover day-to-day cash needs and debt maturities.
“Unfortunately, the union didn’t seriously consider our proposals,” Stephanie Pope, who runs Boeing’s commercial airplane unit, said in a memo shared by the company. “Instead, the union made non-negotiable demands far in excess of what can be accepted if we are to remain competitive as a business.”
Boeing’s shares fell 2.7% as of 9:42 a.m. in New York on Wednesday. The stock had declined about 41% this year through Tuesday’s close, shedding more than $60 billion in market value as the company bounced from crisis to crisis.
Boeing’s now-withdrawn contract proposal, made two weeks ago in a direct approach to workers, offered to hike wages 30% and boost retirement benefits.
Boeing and leaders for IAM District 751 have been in a stalemate over pay and pensions since the union’s 33,000 members walked off the job shortly after midnight on Sept. 13. The company’s first major strike in 16 years has taken a toll on its finances, costing Boeing $100 million a day in lost revenue by TD Cowen’s estimates.
With cash rapidly dwindling while its debt load balloons, Boeing is mulling selling at least $10 billion of new stock once it knows the full extent of the financial damage from the work stoppage, people familiar with the consideration said last week.
Boeing has said that preserving its investment-grade credit rating is an important goal. Junk-rated companies usually face higher borrowing costs than their investment-grade counterparts. Boeing has $4 billion of debt coming due in 2025 and also $8 billion coming due in 2026, according to Moody’s Ratings, which said last month that it’s considering downgrading Boeing to junk.
The company has initiated a savings program that includes furloughs for workers, pay freezes and travel bans. Pope said in her memo that “we do not take these impacts lightly as we take actions and consider next steps.”
The two sides had only picked up negotiations overseen by a mediator again this week after two weeks of stalemate. Throughout the strike over the past weeks, parties made blunders that angered rank-and-file members and complicated efforts to resolve the difference.
The IAM local union’s leadership endorsed the company’s initial offer of a 25% wage increase over four years, well below what many members expected as recompense for repeated below-inflation annual wage rises. The offer also eliminated an annual bonus. IAM members overwhelmingly rejected the offer and voted to strike.
Boeing later misjudged the union’s resolve, bypassing leaders to present an offer directly to workers via the media with an ultimatum that they approve it within days. The terms included a 30% wage increase over four years, reinstating the bonus and boosting the company’s contribution to workers’ 401K retirement plans.
The move backfired by solidifying support for local labor leaders, and encouraging members to dig in on their demand for more pay and better retirement benefits.
In a statement after the latest talks collapsed, the IAM said Boeing refused to propose any further wage increases or reinstate the defined benefit pension.
“By refusing to bargain the offer, the company made it harder to reach an agreement,” the union said. “Your negotiating committee attempted to address multiple priorities that could have led to an offer we could bring to a vote, but the company wasn’t willing to move in our direction.”
–With assistance from Olivia Raimonde.
(Updates shares in the fifth paragraph.)
Most Read from Bloomberg Businessweek
©2024 Bloomberg L.P.
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Shares of Saratoga Investment Corp. SAR rose sharply in today’s pre-market trading after the company reported better-than-expected earnings and sales results for its second quarter.
The company reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of 94 cents per share.
Saratoga Investment shares jumped 7.9% to $25.43 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Gainers
- Carmell Corporation CTCX rose 52.5% to $0.5118 in pre-market trading after dipping 5% on Tuesday.
- WW International, Inc. WW rose 42.4% to $1.65 in pre-market trading. WW shares jumped 47% on Tuesday after the company announced the addition of compounded semaglutide into its offering.
- Arcadium Lithium plc ALTM gained 31.1% to $5.56 in pre-market trading after Rio Tinto RIO announced plans to acquire the company in an all-cash transaction for $5.85 per share.
- Kezar Life Sciences, Inc. KZR shares rose 20.3% to $0.8850 in pre-market trading. Tang Capital Management disclosed a 9.9% active stake in Kezar Life Sciences with 7.2 million shares acquired for $5.6 million.
- iCoreConnect Inc. ICCT shares gained 16.1% to $0.4150 in pre-market trading. iCoreConnect recently announced it acquired substantially all of the assets of the Healthcare Circle of Excellence..
- PLBY Group, Inc. PLBY shares surged 12% to $0.80 in pre-market trading.
- The Oncology Institute, Inc. TOI shares jumped 10.2% to $0.3449 in pre-market trading after declining around 4% on Tuesday.
- IN8bio, Inc. INAB gained 9.5% to $0.2466 in pre-market trading after dipping around 12% on Tuesday.
- Standard Lithium Ltd. SLI rose 7.5% to $1.86 in pre-market trading after declining 8% on Tuesday.
Losers
- Paltalk, Inc. PALT shares dipped 20.2% to $2.45 in pre-market trading after falling around 4% on Tuesday.
- Kidpik Corp. PIK shares declined 19.6% to $1.76 in pre-market trading.
- Moolec Science SA MLEC fell 19.2% to $0.7100 in today’s pre-market trading. The company recently reported a loss for the fourth quarter.
- LeddarTech Holdings Inc LDTC shares fell 18.7% to $0.22 in pre-market trading after gaining 3% on Tuesday.
- Nature’s Miracle Holding Inc. NMHI fell 17% to $0.1632 in pre-market trading after gaining 45% on Tuesday.
- Ambow Education Holding Ltd. AMBO shares declined 15.8% to $3.52 in pre-market trading after gaining 4% on Tuesday.
- Royalty Management Holding Corporation RMCO shares fell 14.7% to $0.7865 in pre-market trading after declining 3% on Tuesday.
- Ontrak, Inc. OTRK shares fell 14.2% to $2.37 after jumping 52% on Tuesday.
- Delek Logistics Partners, LP DKL fell 10.2% to $40.11 in pre-market trading. Delek Logistics Partners priced its public offering of 3,846,153 common units at $39 per unit.
- UP Fintech Holding Limited TIGR declined 7.3% to $8.92 in pre-market trading after dipping around 16% on Tuesday.
Now Read This:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Saxum Real Estate Breaks Ground on Crown Point, IN Location for Arcadia Cold
CHICAGO, Oct. 8, 2024 /PRNewswire/ — Saxum Real Estate has broken ground on a 322,600 square foot cold storage project located in Crown Point, IN for tenant Arcadia Cold, a leading third-party logistics (3PL) provider. FCL Builders is serving as the design-build general contractor for the project. Upon completion, the project will feature 50′ clear height, ample dock space and dock doors to expedite distribution and container handling services, and convertible rooms with temperature capabilities between -10 to 38 degrees F. The facility will contain approximately 45,000 pallet positions and is expected to be delivered in the second quarter of 2026.
“The project will be a mission critical cold storage location.” Sean Gilbert, Principal at Saxum Real Estate
The 26-acre site with I-65 frontage is located in Crown Point, IN, a Chicago submarket with immediate interstate highway access. The property is ideally situated to provide access to large metropolitan centers such as Chicago, Detroit, Indianapolis, Milwaukee, Cleveland, Columbus, Cincinnati, Louisville, St. Louis, and Toronto within a day’s drive.
“The project will be a mission critical cold storage location to service the consolidation of commodity food products and a regional distribution hub for perishable product grown and processed in the region including Indiana, Illinois, Michigan, Ohio, and Canada,” said Sean Gilbert, Principal at Saxum Real Estate.
“The Arcadia Cold team is very excited to announce this new facility in Crown Point,” said JD Schwefler, Arcadia Cold Chief Commercial Officer. “The greater Chicago regional market is critical to our strategy of building out a national distribution network for our customers. This facility, along with another located in a Chicago submarket, which we will announce shortly, will complement each other to serve our customers with regional production and fast-moving consumer packaged goods programs.”
Arcadia Cold is currently the 7th largest cold storage operator in the U.S. To date, Arcadia operates five facilities in Hazleton (PA), Atlanta (GA), Ft. Worth (TX), Phoenix (AZ), and Reno (NV). Arcadia also has additional facilities under construction in Jacksonville (FL) and Charleston (SC).
About Saxum Real Estate
Saxum Real Estate is a national vertically-integrated real estate investment and development firm. Saxum’s portfolio includes a variety of asset classes with total capitalizations surpassing $3.0 billion with over 12MM square feet nationwide. Its current development pipeline totals over $1 billion in capitalization across cold storage, industrial, and multifamily investments.
Saxum is among the most experienced and active cold storage developers in the United States with over $1 billion in total capitalizations and over 3.5MM square feet delivered/under construction. Saxum’s specialized project experience, skillsets and track record allows the firm to execute on highly complex and unique Build-To-Suit (BTS) solutions for Food & Beverage users across the country. www.saxumre.com
About Arcadia Cold
Arcadia Cold specializes in providing third-party handling, storage, distribution, and value-added services to the food industry. We are on a mission to design and deploy modern facilities and provide innovative solutions through the practical application of technology, creating meaningful value for our customers while helping them meet their strategic objectives – establishing The New Age of cold chain. www.arcadiacold.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/saxum-real-estate-breaks-ground-on-crown-point-in-location-for-arcadia-cold-302270566.html
SOURCE Arcadia Cold
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shallow High-Grade Uranium Mineralization Expands at Co.'s Project
Source: Streetwise Reports 10/04/2024
Baselode Energy Corp. BSENF has reported positive uranium assay results from three drill holes of the 2024 drill program at its Ackio prospect, located in the Athabasca Basin, Northern Saskatchewan. These results highlight the shallow depth and high-grade mineralization that continue to characterize the Ackio prospect.
Notably, drill hole AK24-119 intersected 0.28% U3O8 over 21.0 meters, including a high-grade section of 1.55% U3O8 over 1.5 meters at a depth of 141 meters. While drill hole AK24-118 returned 0.59% U3O8 over 8.5 meters, including 1.25% U3O8 over 1.5 meters at a depth of 153 meters.
CEO James Sykes commented in the press release, “These results strengthen our confidence in Ackio. It’s remarkable that, just over three years after discovering Ackio, we’re still achieving better-than-expected grades and widths.”
Baselode expects further assay results from the remaining 40 drill holes to be released after quality review and approval.
Looking At The Uranium Sector
The uranium market has experienced notable growth in recent years. As Kitco wrote on September 25, “Despite recent market corrections, uranium and uranium-related equities have outperformed other asset classes over the long term” with the U3O8 uranium spot price seeing significant rises in the last five years. The long-term fundamentals of the market remained strong, with Kitco noting that “global uranium supply lagging behind demand” could lead to higher prices as utilities are “forced to secure long-term contracts.”
Jeff Clark of The Gold Advisor expressed enthusiasm for the company in an October 3 update, stating that the results from the drill program were better than expected, with high-grade uranium intersected in two keyholes.
Chris Temple of The National Investor similarly commented on September 25, “Uranium and nuclear power are clearly back, with long-term demand increasing, driven by significant developments like the restart of nuclear facilities.”
He observed that the sector appeared to be moving past its consolidation phase. He advised, “Now is the time to rebuild exposure to uranium and nuclear power.”
The Financial Times, also writing on September 25, highlighted the impact of the ongoing geopolitical climate on uranium pricing, stating that “the conversion and enrichment prices are reflecting a much bigger supply squeeze due to the Russia-Ukraine war and other factors.” They also pointed to the increasing prices for nuclear fuel, suggesting that “higher nuclear fuel prices are likely to continue as existing conversion facilities face delays.”
Baselode’s Catalysts
The Ackio prospect remains a strong catalyst for Baselode Energy’s growth, as the shallow and high-grade uranium mineralization continues to yield favorable results. Baselode’s exploration strategy focuses on near-surface, basement-hosted uranium, which offers the potential for low-cost extraction.
As highlighted in the company’s investor presentation, the Ackio discovery includes nine uranium pods, with mineralization starting as shallow as 25 meters below the surface. The ongoing drilling campaign, which has completed over 30,000 meters since 2021, further enhances the company’s resource potential. With over US$20 million in the treasury, Baselode is well-funded to continue advancing Ackio and other projects, including the Catharsis project currently in drilling.
What Third-Party Experts Are Saying
David Talbot, Managing Director at Red Cloud Securities, noted in a September 17 report that drilling at Ackio has “continued to expand the mineralized footprint at Pods 1, 6, and 7” highlighting that “thirteen holes reported composite intervals of anomalous radioactivity between 11m and 42m in thickness.”
In his report, Talbot rated the stock as a Buy and further projected the potential for “8-10-12 million pounds of U3O8 at a grade of ~0.3% U3O8” which aligns with typical grades found in the southeastern part of the Athabasca Basin.
Additionally, Jeff Clark of The Gold Advisor expressed enthusiasm for the company in an October 3 update, stating that the results from the drill program were better than expected, with high-grade uranium intersected in two keyholes. Clark observed that “the stock popped on the news, on heavy volume, investors obviously liking the results.”
He also pointed out that Baselode’s shallow mineralization at Ackio could make future mining operations more economically viable, noting the project’s competitive advantage compared to deeper deposits elsewhere in the Athabasca Basin.
Ownership and Share Structure
According to Refinitiv, Baselode has institutions holding 23.26% with Alps Advisors holding the bulk of it with 17.94%, followed by Vident Investment Advisory LLC at 2.97%. Management and Insiders hold 1.59%. The rest is retail.
The company has a market cap of US$12.63 million, according to Market Watch, with 131.51 free float shares. It trades in the 52-week range between US$0.0778 and US$0.4491.
Important Disclosures:
1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shiba Inu Lead Developer Shytoshi Kusama Reshares Mysterious Post About 'The Last Chapter To My Story'— Is He Hinting At An Exit From Project Or A Potential Moon Run?
Editor’s Note: This story has been updated with a clarification from Shytoshi Kusama.
Shytoshi Kusama, the mysterious lead developer and co-founder of the Shiba Inu SHIB/USD ecosystem, shared a cryptic post, sparking intrigue and speculation in the cryptocurrency community.
What happened: The suspenseful figure reposted a message from another X user, Tsukiyomi Mishima, captioned, “I think this will be the last chapter to my story…”
For the curious, ‘Tsukiyomi’ refers to the god of the moon in Japanese mythology, while ‘Mishima’ could be linked to the author Yukio Mishima.
The post also featured “The Great Wave off Kanagawa” a woodblock print by the artist Hokusai, which was created during the Edo period.
While we don’t know for certain, the message could be alluding to Kusama’s eventual departure from the project, similar to his predecessor Ryoshi, or anticipating SHIB’s journey “to the moon.”
See Also: Kamala Harris On Cannabis And Crypto: Key Questions That Could Be Answered On ’60 Minutes’
While speculations on a potential exit from the project, similar to his predecessor Ryoshi, or anticipation of SHIB’s journey “to the moon” circulated initially, Kusama eventually rejected them.
Why It Matters: Kusama has steered the Shiba Inu ecosystem ever since the abrupt exit of Ryoshi in 2022. However, their real identity remains a mystery, akin to the speculation surrounding Bitcoin BTC/USD creator Satoshi Nakamoto.
Earlier in July, Kusama stated that they were nearing completion of founder Ryoshi’s vision of a completely decentralized system with no leader and that he, too, would “step away from the limelight” at some point.
Price Action: At the time of writing, Shiba Inu was exchanging hands at $0.00001755, down 0.41% in the last 24 hours, according to data from Benzinga Pro.
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Lamar Advertising Company to Release Third Quarter Ended September 30, 2024 Operating Results
BATON ROUGE, La., Oct. 08, 2024 (GLOBE NEWSWIRE) — Lamar Advertising Company LAMR will release its third quarter ended September 30, 2024 earnings report before the market opens on Friday, November 8, 2024. Lamar will host a conference call on Friday, November 8, 2024 at 8:00 a.m. (Central time) to discuss the Company’s results and answer questions relating to company operations.
| Instructions for dialing into Lamar’s conference call are provided below: | |
| All Callers: | 1-800-420-1271 or 1-785-424-1634 |
| Passcode: | 63104 |
| Live Webcast: | www.lamar.com |
| Webcast Replay: | www.lamar.com |
| Available through Friday, November 15, 2024 at 11:59 p.m. Eastern time | |
| Company Contact: | Buster Kantrow |
| Director of Investor Relations | |
| (225) 926-1000 | |
| bkantrow@lamar.com | |
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Exoskeleton Market Size to Hit USD 1863.61 Million by 2033 | Straits Research
New York, United States, Oct. 08, 2024 (GLOBE NEWSWIRE) — Exoskeletons are the rigid exterior coverings of animals, most commonly arthropods. They are non-living due to their composition of chitin and calcium carbonate. Exoskeletons offer structural support and defense against predators, water, and dehydration. However, larger animals would find exoskeletons to be excessively cumbersome. Arthropods, such as crustaceans and beetles, have an exoskeleton on the exterior of their bodies. They lack the internal skeleton present in human bodies. Their skeleton is called an exoskeleton because their ‘bones’ are on the outside, like a suit of Armor. The shell of sponges is another example. It’s called the exoskeleton.
In addition to serving as a protective covering, the exoskeleton or integument of an insect serves as a surface for muscle attachment, an impenetrable barrier against desiccation, and a sensory interface with the surrounding environment. Insects, scorpions, and crustaceans are all examples of the animal class known as arthropods. Exoskeletons are a distinguishing characteristic of arthropods.
Download Free Sample Report PDF @ https://straitsresearch.com/report/exoskeleton-market/request-sample
Market Dynamics
Increasing Incidence of Spinal Cord Injury Drives the Global Market
As patients with spinal cord injuries are advised to use exoskeletons to improve their condition, the incidence of spinal cord injuries propels the market growth for exoskeletons. This has become a significant driver of patient and healthcare provider exoskeleton adoption. According to the World Health Organization, between 250,000 and 500,000 individuals worldwide sustain a spinal cord injury each year, and this rise in patients is causing an increase in the use of exoskeletons.
In addition, the demand for exoskeletons is increasing because they provide several benefits; they enable individuals with spinal cord injuries to experience walking and standing at a low metabolic cost. According to Clinicaltrials.gov, exoskeletons can enhance bowel function and reduce spasticity while assisting with mobility. In addition, continuous exoskeleton use improves physical activity levels and psychological parameters. In addition, previous research indicates that using an exoskeleton at least twice or thrice per week for one to two hours is beneficial for rehabilitating individuals with spinal cord injuries. These advantages are driving the growth of the exoskeleton market.
Exoskeleton Insurance Coverage Is Expanding Creates Tremendous Opportunities
As an integral component of modern medicine and a readily available resource, assistive technology is accessible to patients through various healthcare systems. As a direct result, it is presently available in a substantial number of countries around the world. As the prevalence of robotics in medical procedures increases, certain robotic technologies, such as exoskeletons, are beginning to be covered by health insurance. This category comprises a wide variety of distinct pieces of equipment, including prosthetic limbs and surgical robots, to name a couple.
Regional Analysis
North America is the most significant global exoskeleton market shareholder and is estimated to exhibit a CAGR of 16.7% over the forecast period. Increasing adoption of exoskeletons in the military, healthcare, medical, industrial, and consumer markets is propelling the expansion of the North American exoskeleton market. In addition, the incidence of spinal cord injuries is rising in the region, propelling market expansion. Increasing elderly and disabled populations are among the factors accelerating the adoption of exoskeletons. In addition, government agencies’ high research expenditures in the healthcare sector and continuous technological advancement are driving market growth in the North American region. The presence of private entities that provide funding for R&D to develop technologically advanced products is contributing to the expansion of the market.
In addition, the use of exoskeletons in various industries, such as the medical and military, is increasing. These exoskeletons help infantry personnel carry 17 times their normal carrying capacity with significantly less physical strain. Exoskeletons have numerous medical applications, assisting patients in standing, walking, and carrying large objects.
Europe is anticipated to exhibit a CAGR of 18.4% over the forecast period. In Europe, the high incidence of stroke has been a significant public health concern, resulting in mobility impairment and long-term disability. In addition, a growing elderly population is anticipated to contribute to an increase in exoskeleton usage. The widespread use of exoskeletons in the military, industrial, and manufacturing sectors is anticipated to drive market expansion. Exoskeletons make industrial activities requiring heavy lifting easier.
Additionally, according to the European Foundation for Improvement of Living and Working Conditions, approximately 65 percent of workers spend at least a quarter of their time performing lifting and carrying duties. Low back pain and injuries related to employment are most prevalent among these workers. For industrial purposes, European researchers are interested in developing technologically advanced exoskeletons. Robo-Mate is one such illustration. Thus, the abovementioned factors will stimulate market expansion over the forecast period.
To Gather Additional Insights on the Regional Analysis of the Exoskeleton Market @ https://straitsresearch.com/report/exoskeleton-market/request-sample
Competitive Players
The key players in the global exoskeleton market are Ekso Bionics, Hocoma; Lockheed Martin Corporation; Suit X (U.S. Bionics, Inc.); Rex Bionics Plc.; RB3D; ReWalk Robotics Ltd; Cyberdyne, Inc.; and Active Link (Panasonic Corporation).
Competitive Players
- Ekso Bionics
- Hocoma
- Lockheed Martin Corporation
- Suit X (U.S. Bionics Inc.)
- Rex Bionics Plc.
- RB3D
- ReWalk Robotics Ltd
- Cyberdyne Inc.
- Active Link (Panasonic Corporation).
Recent Developments
- November 2023- XoMotion was created by SFU researchers to be the world’s most advanced exoskeleton for mobility challenges. The technology is poised to offer people with mobility challenges a new chance at free and independent movement.
- September 2023- IIT-D’s Exoskeleton Device RoboExo SMART headed for international footprint. The exoskeleton synchronizes wrist and finger joint movements, significantly enhancing daily functions and minimizing muscle rigidity. Its muscle activity-controlled interface, adaptable settings, and real-time performance feedback promise a journey toward swifter recovery.
Segmentation
- By Mobility
- Mobile
- Fixed/Stationary
- By Technology
- Powered
- Non-Powered
- By Extremity
- Upper Body
- Lower Body
- Full Body
- By End-User
- Healthcare
- Industry
- Military
- By Region
- North America
- Europe
- APAC
- LATAM
- MEA
Get Detailed Market Segmentation @ https://straitsresearch.com/report/exoskeleton-market/segmentation
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.